Literature DB >> 19631530

Design, syntheses, and evaluation of Taspase1 inhibitors.

Jeong Tae Lee1, David Y Chen, Zhimou Yang, Alexander D Ramos, James J-D Hsieh, Matthew Bogyo.   

Abstract

Taspase1 is a threonine protease responsible for cleaving MLL (Mixed-Lineage Leukemia) to achieve proper HOX gene expression. Subsequent studies identified additional Taspase1 substrates including Transcription Factor IIA (TFIIA) and Drosophila HCF. Taspase1 is essential for cell proliferation and is overexpressed in many cancer cell lines. Currently no small molecule inhibitors of this enzyme have been described. Here, we report the synthesis and evaluation of vinyl sulfone, vinyl ketone, epoxy ketone, and boronic acid inhibitors designed based on the preferred Taspase1 cleavage site (Ac-Ile-Ser-Gln-Leu-Asp). Specifically, we evaluated compounds in which the reactive warhead is positioned in place of the P1 aspartic acid side chain as well as at the C-terminus of the peptide. Interestingly, both classes of inhibitors were effective and vinyl ketones and vinyl sulfones showed the greatest potency for the target protease. These results suggest that Taspase1 has unique substrate recognition properties that could potentially be exploited in the design of potent and selective inhibitors of this enzyme.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19631530      PMCID: PMC3513416          DOI: 10.1016/j.bmcl.2009.07.045

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression.

Authors:  James J-D Hsieh; Emily H-Y Cheng; Stanley J Korsmeyer
Journal:  Cell       Date:  2003-10-31       Impact factor: 41.582

2.  Uncleaved TFIIA is a substrate for taspase 1 and active in transcription.

Authors:  Huiqing Zhou; Salvatore Spicuglia; James J-D Hsieh; Dimitra J Mitsiou; Torill Høiby; Gert Jan C Veenstra; Stanley J Korsmeyer; Hendrik G Stunnenberg
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

3.  Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization.

Authors:  James J-D Hsieh; Patricia Ernst; Hediye Erdjument-Bromage; Paul Tempst; Stanley J Korsmeyer
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

4.  Crystal structure of human Taspase1, a crucial protease regulating the function of MLL.

Authors:  Javed A Khan; Ben M Dunn; Liang Tong
Journal:  Structure       Date:  2005-10       Impact factor: 5.006

5.  Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression.

Authors:  Shugaku Takeda; David Y Chen; Todd D Westergard; Jill K Fisher; Jeffrey A Rubens; Satoru Sasagawa; Jason T Kan; Stanley J Korsmeyer; Emily H-Y Cheng; James J-D Hsieh
Journal:  Genes Dev       Date:  2006-09-01       Impact factor: 11.361

6.  Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen.

Authors:  Aaron M LeBeau; Pratap Singh; John T Isaacs; Samuel R Denmeade
Journal:  Chem Biol       Date:  2008-07-21

7.  Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions.

Authors:  Han Liu; Emily H-Y Cheng; James J-D Hsieh
Journal:  Genes Dev       Date:  2007-10-01       Impact factor: 11.361

8.  Species selectivity of mixed-lineage leukemia/trithorax and HCF proteolytic maturation pathways.

Authors:  Francesca Capotosti; James J-D Hsieh; Winship Herr
Journal:  Mol Cell Biol       Date:  2007-08-13       Impact factor: 4.272

9.  Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.

Authors:  Takumi Watanabe; Isao Momose; Masatoshi Abe; Hikaru Abe; Ryuichi Sawa; Yoji Umezawa; Daishiro Ikeda; Yoshikazu Takahashi; Yuzuru Akamatsu
Journal:  Bioorg Med Chem Lett       Date:  2009-03-04       Impact factor: 2.823

10.  Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor.

Authors:  Maha-Hamadien Abdulla; Kee-Chong Lim; Mohammed Sajid; James H McKerrow; Conor R Caffrey
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

View more
  13 in total

1.  A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth.

Authors:  David Y Chen; Yishan Lee; Brian A Van Tine; Adam C Searleman; Todd D Westergard; Han Liu; Ho-Chou Tu; Shugaku Takeda; Yiyu Dong; David R Piwnica-Worms; Kyoung J Oh; Stanley J Korsmeyer; Ann Hermone; Richard Gussio; Robert H Shoemaker; Emily H-Y Cheng; James J-D Hsieh
Journal:  Cancer Res       Date:  2011-12-13       Impact factor: 12.701

2.  Cell-based analysis of structure-function activity of threonine aspartase 1.

Authors:  Carolin Bier; Shirley K Knauer; Alexander Klapthor; Andrea Schweitzer; Alexander Rekik; Oliver H Krämer; Rolf Marschalek; Roland H Stauber
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

3.  Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis.

Authors:  David Y Chen; Han Liu; Shugaku Takeda; Ho-Chou Tu; Satoru Sasagawa; Brian A Van Tine; Dongsi Lu; Emily H-Y Cheng; James J-D Hsieh
Journal:  Cancer Res       Date:  2010-06-01       Impact factor: 12.701

4.  Closantel is an allosteric inhibitor of human Taspase1.

Authors:  Vanessa Luciano; Ewgenij Proschak; Julian D Langer; Stefan Knapp; Jan Heering; Rolf Marschalek
Journal:  iScience       Date:  2021-11-27

5.  Umpolung AlaB Reagents for the Synthesis of Non-Proteogenic Amino Acids, Peptides and Proteins.

Authors:  Feng Zhu; Eric Miller; Wyatt C Powell; Kelly Johnson; Alexander Beggs; Garrett E Evenson; Maciej A Walczak
Journal:  Angew Chem Int Ed Engl       Date:  2022-06-23       Impact factor: 16.823

6.  Organometallic AlaM Reagents for Umpolung Peptide Diversification.

Authors:  Feng Zhu; Wyatt C Powell; Ruiheng Jing; Maciej A Walczak
Journal:  Chem Catal       Date:  2021-06-28

Review 7.  Taspase1: a 'misunderstood' protease with translational cancer relevance.

Authors:  D Wünsch; A Hahlbrock; S Jung; T Schirmeister; J van den Boom; O Schilling; S K Knauer; R H Stauber
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

8.  Bioassays to monitor Taspase1 function for the identification of pharmacogenetic inhibitors.

Authors:  Shirley K Knauer; Verena Fetz; Jens Rabenstein; Sandra Friedl; Bettina Hofmann; Samaneh Sabiani; Elisabeth Schröder; Lena Kunst; Eugen Proschak; Eckhard Thines; Thomas Kindler; Gisbert Schneider; Rolf Marschalek; Roland H Stauber; Carolin Bier
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

9.  Unraveling the Activation Mechanism of Taspase1 which Controls the Oncogenic AF4-MLL Fusion Protein.

Authors:  Samaneh Sabiani; Tim Geppert; Christian Engelbrecht; Eric Kowarz; Gisbert Schneider; Rolf Marschalek
Journal:  EBioMedicine       Date:  2015-04-16       Impact factor: 8.143

10.  Overexpression of the catalytically impaired Taspase1 T234V or Taspase1 D233A variants does not have a dominant negative effect in T(4;11) leukemia cells.

Authors:  Carolin Bier; Rouven Hecht; Lena Kunst; Sabine Scheiding; Désirée Wünsch; Dorothée Goesswein; Günter Schneider; Oliver H Krämer; Shirley K Knauer; Roland H Stauber
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.